Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT06681870
What this trial is testing

ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Who this might be right for
CLDN6-positive Solid TumorOvarian CancerEndometrial Cancer+3 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Study completedNCT01372384
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 6
Early research (Phase 1)WithdrawnNCT03231475
What this trial is testing

Phase I Study of SPH1188-11 in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IV
Shanghai Pharmaceuticals Holding Co., Ltd
Early research (Phase 1)Study completedNCT01199055
What this trial is testing

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Daiichi Sankyo Co., Ltd. 16
Large-scale testing (Phase 3)UnknownNCT04500717
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 460
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149
What this trial is testing

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Who this might be right for
NSCLC
Allist Pharmaceuticals, Inc. 100
Not applicableStudy completedNCT05034926
What this trial is testing

Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 212
Testing effectiveness (Phase 2)UnknownNCT06479759
What this trial is testing

LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLCPD-1
Shanghai Pulmonary Hospital, Shanghai, China 50
Large-scale testing (Phase 3)Study completedNCT01183858
What this trial is testing

Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 315
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Testing effectiveness (Phase 2)Study completedNCT04184921
What this trial is testing

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 216
Testing effectiveness (Phase 2)Study completedNCT02289833
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 49
Large-scale testing (Phase 3)Looking for participantsNCT07662395
What this trial is testing

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Who this might be right for
Double Blind
Sinocelltech Ltd. 410
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Large-scale testing (Phase 3)Looking for participantsNCT07155187
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 490
Not applicableLooking for participantsNCT07510724
What this trial is testing

Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

Who this might be right for
Small Cell Lung Cancer (SCLC)Non-Small Cell Lung Cancer (NSCLC)Lung Cancer (Diagnosis)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 240
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Post-approval studies (Phase 4)Study completedNCT01230710
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 51
Testing effectiveness (Phase 2)Study completedNCT00059722
What this trial is testing

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Genzyme, a Sanofi Company 160
Early research (Phase 1)Study completedNCT01466647
What this trial is testing

The IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Axelar AB 12
Next Page